The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter single-arm phase II study examining the efficacy of TNT for locally advanced rectal cancer: ENSEMBLE-2.
 
Koji Ando
Honoraria - Sanofi
 
Yoshinori Kagawa
Consulting or Advisory Role - Lilly; Merck; Taiho Pharmaceutical
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Mamoru Uemura
No Relationships to Disclose
 
Jun Watanabe
Speakers' Bureau - Johnson & Johnson; Lilly; Medtronic; Takeda
Research Funding - AMCO (Inst); Medtronic (Inst); Stryker (Inst); TERUMO (Inst)
 
Masaaki Miyo
No Relationships to Disclose
 
Yasunori Emi
No Relationships to Disclose
 
Nobuhisa Matsuhashi
Honoraria - Amco; Asahi Kasei; Chugai Pharma; Covidien; Daiichi Sankyo; Gunze Medical; Johnson & Johnson; Kaken Pharmaceutical; Lilly Japan; Merck KGaA; Miyarisan pharmaceutical; MSD; Ono Pharmaceutical; Stryker; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.; Viatris; Yakult Honsha
Research Funding - Abbott (Inst); Asahi Kasei (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Corporation (Inst); EPS Holdings (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Kyowa Kirin (Inst); Lilly Japan (Inst); MSD K.K (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Shift Zero (Inst); Taiho Pharmaceutical (Inst); TERUMO (Inst); Tsumura & Co. (Inst)
 
Naoki Izawa
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; MSD Oncology; Nippon Kayaku; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst)
 
Osamu Muto
No Relationships to Disclose
 
Tatsuya Kinjo
No Relationships to Disclose
 
Yujiro Nishizawa
No Relationships to Disclose
 
Tsuyoshi Hata
No Relationships to Disclose
 
Yusuke Suwa
No Relationships to Disclose
 
Takuya Honboh
No Relationships to Disclose
 
Jesse Yu Tajima
No Relationships to Disclose
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Incyte; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Merck; MSD K.K
Research Funding - Chugai Pharma; Taiho Pharmaceutical
 
Koji Oba
Honoraria - Asahi Kasei; Boehringer Ingelheim; Chugai Pharma; Janssen; Ono Pharmaceutical
 
Ichiro Takemasa
No Relationships to Disclose
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health